Clinical Trial News
Wednesday, July 25th, 2012
Pharmaphorum.com: 7/24/12. Angela Dunn interviews Dr Tomasz Sablinski Angela Dunn interviews Dr Tomasz Sablinski, the Founder and CEO of Transparency Life Sciences, the world’s first drug development company based on Open Innovation (OI). According to the “2012 State of Global Open Innovation“, Forrester defines Open Innovation (OI) as: “Innovation efforts that leverage external partners, ideas, […]
Clinical Trial News
Wednesday, July 25th, 2012
San Jose, California (PRWEB) July 23, 2012 Due to narrowing drug pipelines, expiring patents of popular drugs, and a scarcity of prospective drug launches, the pharmaceutical industry is actively seeking tools that can quicken the drug discovery procedure and boost productivity. Though ongoing research is predicted to help detect additional drug candidates, the rise in […]
Clinical Trial News
Wednesday, July 25th, 2012
N Engl J Med 2012; Jerry Avorn, M.D.July 19, 2012 The history of medicine is largely the story of medicines — a continuing tale of unfolding risks and benefits. Yet the medical world into which the Journal was born in 1812 did not systematically assess the side effects of treatments in relation to the good they did. […]
Clinical Trial News
Wednesday, July 25th, 2012
Europa.eu: July 17, 2012 What are clinical trials? Clinical trials are a vital step in the development of new and safe medicines and in improving medical treatment. Human volunteers are enrolled in a clinical trial for the following reasons: to test the safety and effectiveness of new medicines, to test new indications for existing medicines or […]
Clinical Trial News
Wednesday, July 25th, 2012
Annonc.oxfordjournals.org: 7/17/12. Inclusion in clinical trials is generally viewed as best practice for most newly diagnosed childhood cancers, but the impact on population-based survival has rarely been examined. Patients and methods The population-based data were analysed for 25 853 children (66% of all registered childhood cancers) diagnosed in Britain during 1978–2005 with acute lymphoblastic leukaemia (ALL), acute myeloid […]
Clinical Trial News
Saturday, July 21st, 2012
July 16, 2012 in Econometrics The benefit of randomized controlled trials is that one can identify the causal effect of a certain treatment in the absence of selection effects (assuming the randomization is properly done). However, RCT results often do not generalize to the larger population. Reasons for this include: The RCT population may not be representative […]
Clinical Trial News
Saturday, July 21st, 2012
Pharmaphorum.com: Rebecca Budd, TrialAdvance, Inc. Rebecca Budd shares her opinions on some of the reasons behind underrepresentation in clinical trials in the United States, from both a patient and a sponsor perspective. She also provides her thoughts on the future of clinical trials for the pharmaceutical industry, if they continue in the same way. Twenty years ago, […]
Clinical Trial News
Saturday, July 21st, 2012
No Differences in Quality of Clinical Trial Data Across Regions, Reports Drug Information Journal Acrohealth.org: July 12, 2012 – WASHINGTON, DC – “A formal statistical evaluation indicates no significant differences in data quality for clinical trials conducted in developing regions relative to mature regions,” says an article published in the July 2012 issue of the Drug Information Journal. The article by Pankaj […]
Clinical Trial News
Saturday, July 21st, 2012
BMC Medical Ethics 2012, 13:16 doi:10.1186/1472-6939-13-16 -Published: 8 July 2012. The requirement that animals be used in research and testing in order to protect humans was formalized in the Nuremberg Code and subsequent national and international laws, codes, and declarations. Discussion We review the history of these requirements and contrast what was known via science about animal models […]
Clinical Trial News
Saturday, July 21st, 2012
The Society for Clinical Trials: July 3, 2012. The Institute of Medicine (IOM) has recommended that each person with cancer should have access to clinical trials, which have been associated with improving care quality and disparities. With no effective enrollment monitoring system, patterns of trial enrollment remain unclear. Purpose We developed a population-based, statewide system designed to […]
